First Time Loading...
B

BioLine RX Ltd
TASE:BLRX

Watchlist Manager
BioLine RX Ltd
TASE:BLRX
Watchlist
Price: 18.1 ILS 5.23% Market Closed
Updated: May 28, 2024

BioLine RX Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BioLine RX Ltd
Net Income (Common) Peer Comparison

Comparables:
CLGN
KMDA
URGN
ENTX
B
BONS

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
B
BioLine RX Ltd
TASE:BLRX
Net Income (Common)
-$60.6m
CAGR 3-Years
-26%
CAGR 5-Years
-21%
CAGR 10-Years
-14%
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Net Income (Common)
-$7m
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Net Income (Common)
$12.5m
CAGR 3-Years
-5%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Net Income (Common)
-$104.3m
CAGR 3-Years
4%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Net Income (Common)
-$8.9m
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Net Income (Common)
-₪28.5m
CAGR 3-Years
-9%
CAGR 5-Years
-9%
CAGR 10-Years
-11%

See Also

What is BioLine RX Ltd's Net Income (Common)?
Net Income (Common)
-60.6m USD

Based on the financial report for Dec 31, 2023, BioLine RX Ltd's Net Income (Common) amounts to -60.6m USD.

What is BioLine RX Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-14%

Over the last year, the Net Income (Common) growth was -143%. The average annual Net Income (Common) growth rates for BioLine RX Ltd have been -26% over the past three years , -21% over the past five years , and -14% over the past ten years .